Table 1.
Patients' characteristics
| Characteristics | No. | Percent (%) |
|---|---|---|
| Age, years | ||
| Median | 58 | |
| Range | 31–75 | |
| Sex | ||
| Female | 14 | 50.0 |
| Male | 14 | 50.0 |
| Smoking | ||
| Yes | 8 | 28.6 |
| No | 20 | 71.4 |
| Initial EGFR mutation | ||
| 19del | 16 | 57.1 |
| L858 | 10 | 35.7 |
| 21L861Q/18G719X | 1 | 3.6 |
| 19del/T790M | 1 | 3.6 |
| Prior EGFR TKI | ||
| Gefitinib | 11 | 39.3 |
| Erlotinib | 2 | 7.1 |
| Icotinib | 14 | 50.0 |
| None† | 1 | 3.6 |
| Line of first generation TKIs | ||
| First | 23 | 85.2 |
| Second | 4 | 14.8 |
| Dose of abivertinib | ||
| 150 mg bid | 2 | 12.5 |
| 200 mg bid | 5 | 31.3 |
| 250 mg bid | 4 | 25.0 |
| 300 mg bid | 17 | 31.5 |
| Salvage therapy after abivertinib | ||
| Yes | 15 | 53.6 |
| No | 12 | 42.9 |
| Unknown | 1 | 3.6 |
†
The patient had de novo T790M mutation.